Newsfeeds Archive - Page 40 of 56

2 minute read

Psyence, Revive Therapeutics Ink Private Placements: Capital To Support Drug Trials

December 16, 5:46 PM

Life sciences biotech Psyence Group Inc. (OTCQB: PSYGF) has closed the second tranche of its previously announced private placement of up to $2.2 million (CA$3 million).

PSYGF

2 minute read

FDA OKs Ketamine For Treating Organ Transplant Injuries With ‘Orphan Drug’ Status

By Lara Goldstein

December 15, 3:12 PM

The U.S. Food and Drug Administration (FDA) has granted PharmaTher Holdings Ltd. (OTCQB: PHRRF) an Orphan Drug designation for ketamine in the prevention of injury from organ transplantation.

PHRRF

1 minute read

Psychedelics Company Filament Signs Licensing Deal With Psyence In US, UK And EU

By Lara Goldstein

December 15, 2:38 PM

Filament Health Corp. (OTCQB: FLHLF) and Psyence Group Inc. (OTCQB: PSYGF) have inked a worldwide commercial licensing deal.

FLHLF

3 minute read

EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans

By Lara Goldstein

December 15, 1:48 PM

Part one of a three-part series. The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.

AGNPF

2 minute read

UK Supports Psychedelic Research With Phase 3 Trial In Federal Health Sites

By Lara Goldstein

December 13, 4:35 PM

Awakn Life Sciences Corp.

AWKNF

6 minute read

Psyched: Psychedelic Therapy In The Workplace, UCL’s Brain Imaging Study, COMPASS Trials And More

By Lara Goldstein

December 13, 4:21 PM

Psychedelic Therapy Now Available As Workplace Benefit, Free Month For Laid-Off Tech Workers

CMPS

2 minute read

Psychedelic Company Sale: Mydecine Gets Over $2.5M For Wholly-Owned Tech Subsidiary Business

By Lara Goldstein

December 13, 2:47 PM

Mydecine Innovations Group Inc.

MYCOF

2 minute read

Psychedelics & Environmental Protection: Company Seeks Patents To Synthetically Produce Toad Venom

By Lara Goldstein

December 12, 2:56 PM

Psychedelic therapeutics biotech company PsyBio Therapeutics Corp. (OTCQB: PSYBF) has filed three additional U.S.

PSYBF

3 minute read

Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far

By Lara Goldstein

December 12, 1:25 PM

Mental health care company COMPASS Pathways plc (NASDAQ: CMPS) has announced positive data demonstrating the potential of its proprietary synthetic psilocybin compound COMP360 in treating depression within Type II bipolar disorder.

CMPS

4 minute read

Colorado’s Psychedelics Legal Scenario: Insurance & State Aid, Advisory Board And Local Regulations

By Lara Goldstein

December 9, 3:39 PM

Part three of three-part series. See previous stories: Colorado's New Psychedelics Regulations: Co-Author Of The Bill Replies To Concerns

CMPS